BG107364A - Crf2 лиганди в комбинирана терапия - Google Patents

Crf2 лиганди в комбинирана терапия Download PDF

Info

Publication number: BG107364A
Authority: BG; Bulgaria
Prior art keywords: crf; receptor; receptor ligand; crfi; disorder
Prior art date: 2000-07-19

Application number

BG107364A

Other languages

Bulgarian (bg)

English (en)

Inventor

Siew HO

Original Assignee

Bristol-Myers Squibb Pharma Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-19

Filing date

2002-12-09

Publication date

2003-07-31

2002-12-09 Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company

2003-07-31 Publication of BG107364A publication Critical patent/BG107364A/bg

Links

239000003446 ligand Substances 0.000 title claims description 258
238000002648 combination therapy Methods 0.000 title claims 3
108020003175 receptors Proteins 0.000 claims abstract description 509
239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 180
238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 180
108020004999 messenger RNA Proteins 0.000 claims abstract description 58
108020000948 Antisense Oligonucleotides Proteins 0.000 claims abstract description 54
208000020016 psychiatric disease Diseases 0.000 claims abstract description 36
208000019899 phobic disease Diseases 0.000 claims abstract description 29
210000004556 brain Anatomy 0.000 claims abstract description 22
208000028173 post-traumatic stress disease Diseases 0.000 claims abstract description 16
108090000623 proteins and genes Proteins 0.000 claims abstract description 16
208000019906 panic disease Diseases 0.000 claims abstract description 14
208000019901 Anxiety disease Diseases 0.000 claims abstract description 13
230000036506 anxiety Effects 0.000 claims abstract description 12
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims abstract description 10
239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims abstract description 10
241000283984 Rodentia Species 0.000 claims abstract description 10
238000001727 in vivo Methods 0.000 claims abstract description 10
210000003169 central nervous system Anatomy 0.000 claims abstract description 8
108091005470 CRHR2 Proteins 0.000 claims abstract 2
102000005962 receptors Human genes 0.000 claims description 508
108091034117 Oligonucleotide Proteins 0.000 claims description 243
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 148
208000035475 disorder Diseases 0.000 claims description 134
230000000694 effects Effects 0.000 claims description 123
150000003839 salts Chemical class 0.000 claims description 97
229940002612 prodrug Drugs 0.000 claims description 88
239000000651 prodrug Substances 0.000 claims description 88
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 76
125000003729 nucleotide group Chemical group 0.000 claims description 69
238000000034 method Methods 0.000 claims description 62
230000000692 anti-sense effect Effects 0.000 claims description 61
239000005547 deoxyribonucleotide Substances 0.000 claims description 53
241000700159 Rattus Species 0.000 claims description 36
108091005471 CRHR1 Proteins 0.000 claims description 35
241001465754 Metazoa Species 0.000 claims description 34
150000001875 compounds Chemical class 0.000 claims description 34
239000005557 antagonist Substances 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 31
108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 claims description 30
150000004713 phosphodiesters Chemical class 0.000 claims description 28
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 28
238000012360 testing method Methods 0.000 claims description 25
230000027455 binding Effects 0.000 claims description 22
230000006399 behavior Effects 0.000 claims description 20
238000002474 experimental method Methods 0.000 claims description 20
108090000765 processed proteins & peptides Proteins 0.000 claims description 20
206010026749 Mania Diseases 0.000 claims description 19
108020004707 nucleic acids Proteins 0.000 claims description 19
102000039446 nucleic acids Human genes 0.000 claims description 19
150000007523 nucleic acids Chemical class 0.000 claims description 19
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 18
239000002773 nucleotide Substances 0.000 claims description 18
230000000949 anxiolytic effect Effects 0.000 claims description 17
230000005764 inhibitory process Effects 0.000 claims description 17
238000009396 hybridization Methods 0.000 claims description 16
230000035939 shock Effects 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 14
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 13
239000004952 Polyamide Substances 0.000 claims description 13
229940079593 drug Drugs 0.000 claims description 13
230000002401 inhibitory effect Effects 0.000 claims description 13
230000001404 mediated effect Effects 0.000 claims description 13
229920002647 polyamide Polymers 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 13
229940044551 receptor antagonist Drugs 0.000 claims description 13
239000002464 receptor antagonist Substances 0.000 claims description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
206010012335 Dependence Diseases 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
239000000556 agonist Substances 0.000 claims description 12
230000000338 anxiogenic effect Effects 0.000 claims description 12
206010015037 epilepsy Diseases 0.000 claims description 12
239000011780 sodium chloride Substances 0.000 claims description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
230000015556 catabolic process Effects 0.000 claims description 11
238000006731 degradation reaction Methods 0.000 claims description 11
230000003961 neuronal insult Effects 0.000 claims description 11
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
-1 -modified ribonucleotide phosphodiester Chemical class 0.000 claims description 10
208000024827 Alzheimer disease Diseases 0.000 claims description 10
208000023105 Huntington disease Diseases 0.000 claims description 10
208000018737 Parkinson disease Diseases 0.000 claims description 10
230000009471 action Effects 0.000 claims description 10
239000002249 anxiolytic agent Substances 0.000 claims description 10
229940049706 benzodiazepine Drugs 0.000 claims description 10
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
239000002336 ribonucleotide Substances 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
201000006474 Brain Ischemia Diseases 0.000 claims description 9
206010008120 Cerebral ischaemia Diseases 0.000 claims description 9
102100021752 Corticoliberin Human genes 0.000 claims description 9
206010019196 Head injury Diseases 0.000 claims description 9
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 9
208000013016 Hypoglycemia Diseases 0.000 claims description 9
208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 9
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 9
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 9
201000004810 Vascular dementia Diseases 0.000 claims description 9
230000002490 cerebral effect Effects 0.000 claims description 9
206010008118 cerebral infarction Diseases 0.000 claims description 9
229960003920 cocaine Drugs 0.000 claims description 9
229960002069 diamorphine Drugs 0.000 claims description 9
231100000318 excitotoxic Toxicity 0.000 claims description 9
230000003492 excitotoxic effect Effects 0.000 claims description 9
230000000971 hippocampal effect Effects 0.000 claims description 9
208000026278 immune system disease Diseases 0.000 claims description 9
208000028867 ischemia Diseases 0.000 claims description 9
230000000302 ischemic effect Effects 0.000 claims description 9
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 9
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 9
208000000103 Anorexia Nervosa Diseases 0.000 claims description 8
229920003091 Methocel™ Polymers 0.000 claims description 8
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
238000013507 mapping Methods 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
230000001629 suppression Effects 0.000 claims description 8
208000007101 Muscle Cramp Diseases 0.000 claims description 7
206010039966 Senile dementia Diseases 0.000 claims description 7
208000005392 Spasm Diseases 0.000 claims description 7
206010046543 Urinary incontinence Diseases 0.000 claims description 7
230000000295 complement effect Effects 0.000 claims description 7
208000020431 spinal cord injury Diseases 0.000 claims description 7
231100000331 toxic Toxicity 0.000 claims description 7
230000002588 toxic effect Effects 0.000 claims description 7
230000004580 weight loss Effects 0.000 claims description 7
241000699660 Mus musculus Species 0.000 claims description 6
208000006011 Stroke Diseases 0.000 claims description 6
108010059705 Urocortins Proteins 0.000 claims description 6
102000005630 Urocortins Human genes 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
230000003042 antagnostic effect Effects 0.000 claims description 6
108010063987 astressin Proteins 0.000 claims description 6
HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 claims description 6
230000004071 biological effect Effects 0.000 claims description 6
230000004064 dysfunction Effects 0.000 claims description 6
239000006274 endogenous ligand Substances 0.000 claims description 6
230000001965 increasing effect Effects 0.000 claims description 6
230000007310 pathophysiology Effects 0.000 claims description 6
230000003389 potentiating effect Effects 0.000 claims description 6
210000001519 tissue Anatomy 0.000 claims description 6
238000011830 transgenic mouse model Methods 0.000 claims description 6
239000000777 urocortin Substances 0.000 claims description 6
INZDAHMZPGDOAR-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical compound OP(O)(O)=S.CC#CC1=CNC(=O)NC1=O INZDAHMZPGDOAR-UHFFFAOYSA-N 0.000 claims description 5
108010059089 antisauvagine 30 Proteins 0.000 claims description 5
238000000376 autoradiography Methods 0.000 claims description 5
230000003542 behavioural effect Effects 0.000 claims description 5
238000013461 design Methods 0.000 claims description 5
QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 claims description 4
241000272517 Anseriformes Species 0.000 claims description 4
241000906446 Theraps Species 0.000 claims description 4
KFUIXDNQSMKKJQ-ZLFMSJRASA-N chembl439883 Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)CNC(=O)[C@H]2NC(=O)CC2)CCC1 KFUIXDNQSMKKJQ-ZLFMSJRASA-N 0.000 claims description 4
238000007901 in situ hybridization Methods 0.000 claims description 4
230000002197 limbic effect Effects 0.000 claims description 4
238000001243 protein synthesis Methods 0.000 claims description 4
238000012552 review Methods 0.000 claims description 4
108010086511 sauvagine Proteins 0.000 claims description 4
230000014616 translation Effects 0.000 claims description 4
108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
229940122010 Corticotropin releasing factor antagonist Drugs 0.000 claims description 3
102100034343 Integrase Human genes 0.000 claims description 3
101710203526 Integrase Proteins 0.000 claims description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 3
206010047700 Vomiting Diseases 0.000 claims description 3
150000007513 acids Chemical class 0.000 claims description 3
230000000578 anorexic effect Effects 0.000 claims description 3
230000001430 anti-depressive effect Effects 0.000 claims description 3
230000006396 anxiogenic response Effects 0.000 claims description 3
238000004891 communication Methods 0.000 claims description 3
230000001143 conditioned effect Effects 0.000 claims description 3
239000002769 corticotropin releasing factor antagonist Substances 0.000 claims description 3
230000002068 genetic effect Effects 0.000 claims description 3
230000002218 hypoglycaemic effect Effects 0.000 claims description 3
210000003016 hypothalamus Anatomy 0.000 claims description 3
230000028993 immune response Effects 0.000 claims description 3
238000012613 in situ experiment Methods 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
102000006240 membrane receptors Human genes 0.000 claims description 3
230000004060 metabolic process Effects 0.000 claims description 3
210000002569 neuron Anatomy 0.000 claims description 3
238000012261 overproduction Methods 0.000 claims description 3
239000008177 pharmaceutical agent Substances 0.000 claims description 3
230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
108091006082 receptor inhibitors Proteins 0.000 claims description 3
239000003488 releasing hormone Substances 0.000 claims description 3
239000000758 substrate Substances 0.000 claims description 3
230000002194 synthesizing effect Effects 0.000 claims description 3
230000008673 vomiting Effects 0.000 claims description 3
230000009910 autonomic response Effects 0.000 claims description 2
231100000673 dose–response relationship Toxicity 0.000 claims description 2
230000009977 dual effect Effects 0.000 claims description 2
208000027418 Wounds and injury Diseases 0.000 claims 7
230000006378 damage Effects 0.000 claims 7
208000014674 injury Diseases 0.000 claims 7
230000001537 neural effect Effects 0.000 claims 7
239000000018 receptor agonist Substances 0.000 claims 5
229940044601 receptor agonist Drugs 0.000 claims 5
238000006467 substitution reaction Methods 0.000 claims 5
125000002637 deoxyribonucleotide group Chemical group 0.000 claims 3
208000019022 Mood disease Diseases 0.000 claims 2
LBWQSAZEYIZZCE-SNVBAGLBSA-N Pexacerfont Chemical compound CC1=NN2C(N[C@H](C)CC)=NC(C)=NC2=C1C1=CC=C(OC)N=C1C LBWQSAZEYIZZCE-SNVBAGLBSA-N 0.000 claims 2
230000002708 enhancing effect Effects 0.000 claims 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
210000003205 muscle Anatomy 0.000 claims 2
210000000278 spinal cord Anatomy 0.000 claims 2
KNIWBMMJSJHUJB-UHFFFAOYSA-N 2-(3,5-dimethoxy-4-prop-2-ynoxyphenyl)ethanamine Chemical class COC1=CC(CCN)=CC(OC)=C1OCC#C KNIWBMMJSJHUJB-UHFFFAOYSA-N 0.000 claims 1
102000004877 Insulin Human genes 0.000 claims 1
108090001061 Insulin Proteins 0.000 claims 1
208000012981 Traumatic Stress disease Diseases 0.000 claims 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
208000026345 acute stress disease Diseases 0.000 claims 1
230000001270 agonistic effect Effects 0.000 claims 1
229940125396 insulin Drugs 0.000 claims 1
235000021190 leftovers Nutrition 0.000 claims 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
239000002585 base Substances 0.000 description 11
230000009467 reduction Effects 0.000 description 9
231100000862 numbness Toxicity 0.000 description 8
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000006870 function Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
230000007017 scission Effects 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000008685 targeting Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
229920005372 Plexiglas® Polymers 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000002635 electroconvulsive therapy Methods 0.000 description 3
238000000185 intracerebroventricular administration Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
241001631457 Cannula Species 0.000 description 2
102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
101000878664 Homo sapiens Corticotropin-releasing factor receptor 2 Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
229960003121 arginine Drugs 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
238000009510 drug design Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
210000003140 lateral ventricle Anatomy 0.000 description 2
229960003646 lysine Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
GHPCICSQWQDZLM-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonyl-1-methyl-3-propylurea Chemical compound CCCNC(=O)N(C)S(=O)(=O)C1=CC=C(Cl)C=C1 GHPCICSQWQDZLM-UHFFFAOYSA-N 0.000 description 1
HFJMJLXCBVKXNY-IVZWLZJFSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 HFJMJLXCBVKXNY-IVZWLZJFSA-N 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
IYXGAVFNZJFSBQ-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)C(O)C(O)C(O)=O IYXGAVFNZJFSBQ-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
ZRFXOICDDKDRNA-IVZWLZJFSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 ZRFXOICDDKDRNA-IVZWLZJFSA-N 0.000 description 1
ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001479434 Agfa Species 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
XUQUNBOKLNVMMK-UHFFFAOYSA-N [5-[6-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyhexylcarbamoyl]-6'-(2,2-dimethylpropanoyloxy)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] 2,2-dimethylpropanoate Chemical compound C12=CC=C(OC(=O)C(C)(C)C)C=C2OC2=CC(OC(=O)C(C)(C)C)=CC=C2C21OC(=O)C1=CC(C(=O)NCCCCCCOP(N(C(C)C)C(C)C)OCCC#N)=CC=C21 XUQUNBOKLNVMMK-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
238000001818 capillary gel electrophoresis Methods 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000008451 emotion Effects 0.000 description 1
230000002616 endonucleolytic effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001036 exonucleolytic effect Effects 0.000 description 1
230000021824 exploration behavior Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000005187 foaming Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229940114119 gentisate Drugs 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
230000007659 motor function Effects 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
125000005487 naphthalate group Chemical group 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
229940039748 oxalate Drugs 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
229940069575 rompun Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
229940007718 zinc hydroxide Drugs 0.000 description 1
229910021511 zinc hydroxide Inorganic materials 0.000 description 1
LJGOZJHDEQHJRI-SITYYSIOSA-N α-helical crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(C)C)C1=CNC=N1 LJGOZJHDEQHJRI-SITYYSIOSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG107364A 2000-07-19 2002-12-09 Crf2 лиганди в комбинирана терапия BG107364A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21939100P	2000-07-19	2000-07-19
PCT/US2001/022808 WO2002005749A2 (en)	2000-07-19	2001-07-19	Crf2 ligands in combination therapy

Publications (1)

Publication Number	Publication Date
BG107364A true BG107364A (bg)	2003-07-31

Family

ID=22819077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107364A BG107364A (bg)	2000-07-19	2002-12-09	Crf2 лиганди в комбинирана терапия

Country Status (20)

Country	Link
US (2)	US20020035083A1 (is)
EP (1)	EP1383460A2 (is)
JP (1)	JP2004513880A (is)
KR (1)	KR20040014926A (is)
CN (1)	CN1501976A (is)
AU (1)	AU2001280632A1 (is)
BG (1)	BG107364A (is)
BR (1)	BR0111937A (is)
CA (1)	CA2416986A1 (is)
CZ (1)	CZ2003159A3 (is)
EE (1)	EE200300025A (is)
HU (1)	HUP0301833A3 (is)
IL (1)	IL153264A0 (is)
IS (1)	IS6673A (is)
MX (1)	MXPA02012721A (is)
NO (1)	NO20030214L (is)
PL (1)	PL365955A1 (is)
RU (1)	RU2003104509A (is)
WO (1)	WO2002005749A2 (is)
ZA (1)	ZA200300088B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007073149A1 (en) *	2005-12-22	2007-06-28	Keygene N.V.	Alternative nucleotides for improved targeted nucleotide exchange
JP2009528289A (ja) *	2006-02-27	2009-08-06	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
EP2167094A2 (en) *	2007-06-13	2010-03-31	Research Development Foundation	Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
CN104231059B (zh) *	2013-06-19	2016-12-28	深圳翰宇药业股份有限公司	一种多肽及其制备方法和用途
KR20190084055A (ko) *	2016-10-20	2019-07-15	코르텐 인코포레이티드	부적응 스트레스 반응에서 기인한 질환의 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4605642A (en) *	1984-02-23	1986-08-12	The Salk Institute For Biological Studies	CRF antagonists
US5063245A (en) *	1990-03-28	1991-11-05	Nova Pharmaceutical Corporation	Corticotropin-releasing factor antagonism compounds
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
ATE171212T1 (de) *	1994-06-14	1998-10-15	Neurocrine Biosciences Inc	Corticotropin freisetzende rezeptoren des faktor 2
US5786203A (en) *	1994-06-14	1998-07-28	Neurocrine Biosciences, Inc.	Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) *	1994-12-12	1997-09-02	The Salk Institute For Biological Studies	Cyclic CRF analogs
US6214797B1 (en) *	1995-06-13	2001-04-10	The Salk Institute For Biological Studies	Urocortin peptides, nucleic acid encoding same methods for using same
US6051578A (en) *	1996-02-12	2000-04-18	Pfizer Inc.	Pyrazolopyrimidines for treatment of CNS disorders
ZA973884B (en) *	1996-05-23	1998-11-06	Du Pont Merck Pharma	Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US5861398A (en) *	1996-08-26	1999-01-19	Alanex Corporation	Benzoperimidine-carboxylic acids and derivatives thereof
GB9717087D0 (en) *	1997-08-12	1997-10-15	Ciba Geigy Ag	Improvements in or relating to organic compounds

2001
- 2001-07-19 BR BR0111937-0A patent/BR0111937A/pt not_active IP Right Cessation
- 2001-07-19 HU HU0301833A patent/HUP0301833A3/hu unknown
- 2001-07-19 IL IL15326401A patent/IL153264A0/xx unknown
- 2001-07-19 CA CA002416986A patent/CA2416986A1/en not_active Abandoned
- 2001-07-19 EP EP01959036A patent/EP1383460A2/en not_active Withdrawn
- 2001-07-19 CN CNA01814084XA patent/CN1501976A/zh active Pending
- 2001-07-19 RU RU2003104509/14A patent/RU2003104509A/ru not_active Application Discontinuation
- 2001-07-19 KR KR10-2003-7000716A patent/KR20040014926A/ko not_active Withdrawn
- 2001-07-19 CZ CZ2003159A patent/CZ2003159A3/cs unknown
- 2001-07-19 JP JP2002511684A patent/JP2004513880A/ja active Pending
- 2001-07-19 US US09/908,825 patent/US20020035083A1/en not_active Abandoned
- 2001-07-19 WO PCT/US2001/022808 patent/WO2002005749A2/en not_active Ceased
- 2001-07-19 PL PL01365955A patent/PL365955A1/xx not_active Application Discontinuation
- 2001-07-19 AU AU2001280632A patent/AU2001280632A1/en not_active Abandoned
- 2001-07-19 MX MXPA02012721A patent/MXPA02012721A/es unknown
- 2001-07-19 EE EEP200300025A patent/EE200300025A/xx unknown
2002
- 2002-12-09 BG BG107364A patent/BG107364A/bg unknown
2003
- 2003-01-03 ZA ZA200300088A patent/ZA200300088B/en unknown
- 2003-01-08 IS IS6673A patent/IS6673A/is unknown
- 2003-01-16 NO NO20030214A patent/NO20030214L/no not_active Application Discontinuation
2004
- 2004-08-26 US US10/926,558 patent/US20050059627A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1501976A (zh)	2004-06-02
NO20030214D0 (no)	2003-01-16
KR20040014926A (ko)	2004-02-18
HUP0301833A3 (en)	2005-12-28
CZ2003159A3 (cs)	2004-02-18
IS6673A (is)	2003-01-08
US20020035083A1 (en)	2002-03-21
MXPA02012721A (es)	2003-04-25
JP2004513880A (ja)	2004-05-13
EP1383460A2 (en)	2004-01-28
EE200300025A (et)	2005-04-15
CA2416986A1 (en)	2002-01-24
RU2003104509A (ru)	2004-08-27
WO2002005749A3 (en)	2003-11-06
US20050059627A1 (en)	2005-03-17
PL365955A1 (en)	2005-01-24
BR0111937A (pt)	2005-04-12
HUP0301833A2 (hu)	2003-09-29
AU2001280632A1 (en)	2002-01-30
NO20030214L (no)	2003-01-16
ZA200300088B (en)	2005-05-09
IL153264A0 (en)	2003-07-06
WO2002005749A2 (en)	2002-01-24

Publication	Publication Date	Title
JP7851349B2 (ja)	2026-04-24	Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド
US7662948B2 (en)	2010-02-16	Antisense oligonucleotides against VR1
US20090082297A1 (en)	2009-03-26	Compositions and Methods for Regulating Gene Expression
JP2018052981A (ja)	2018-04-05	真核細胞におけるエキソンスキッピングの誘導
JP2015518712A (ja)	2015-07-06	Ｍｅｃｐ２発現を調節するための組成物及び方法
JP2015523853A (ja)	2015-08-20	Ａｔｐ２ａ２発現を調節するための組成物及び方法
JP2015518713A (ja)	2015-07-06	Ｕｔｒｎ発現を調節するための組成物及び方法
JP2015518711A (ja)	2015-07-06	Ｂｄｎｆ発現を調節するための組成物及び方法
US20190376064A1 (en)	2019-12-12	Genetic and Pharmacological Transcriptional Upregulation of the Repressed FXN Gene as a Therapeutic Strategy for Friedreich Ataxia
US6312684B1 (en)	2001-11-06	Method of inducing resistance to tumor growth
US8178507B2 (en)	2012-05-15	Method for the modulation of function of transcription factors
US20200054746A1 (en)	2020-02-20	Methods for increasing neuronal survival
BG107364A (bg)	2003-07-31	Crf2 лиганди в комбинирана терапия
AU2006345724B2 (en)	2013-11-21	Compositions and methods for the treatment of muscle wasting
HK1250243A1 (zh)	2018-12-07	治疗方法
CA2457131A1 (en)	2002-02-21	Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof
US20230025878A1 (en)	2023-01-26	Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors
Wright et al.	1999	κ-Opioid receptor antisense oligonucleotide injected into rat hippocampus causes hypertension
WO2000042178A2 (en)	2000-07-20	Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function
EP1485117A2 (en)	2004-12-15	Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
WO2024112653A1 (en)	2024-05-30	Inhibitory nucleic acids and methods of use thereof
US20080293653A1 (en)	2008-11-27	Method of treating autoimmune diseases